Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer

[1] Beatson GT(1896)On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases Trans Med Chir Soc Edinb. 15 153-179

[2] Davies C(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[3] Godwin J(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816

[4] Gray R(2010)Intrinsic resistance to chemotherapy in breast cancer Womens Health (Lond). 6 821-830

[5] Clarke M(2012)Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 2601-2608

[6] Cutter D(2013)Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis Ann Oncol 24 101-108

[7] Davies C(2017)Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy Oncotarget 8 55550-55561

[8] Pan H(2017)Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy Anticancer Res 37 4859-4865

[9] Godwin J(2009)Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer Br J Cancer 101 1529-1536

[10] Gray R(2015)Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes Clin Breast Cancer 15 153-160

[1] Beatson GT(1896)On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases Trans Med Chir Soc Edinb. 15 153-179

[2] Davies C(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[3] Godwin J(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816

[4] Gray R(2010)Intrinsic resistance to chemotherapy in breast cancer Womens Health (Lond). 6 821-830

[5] Clarke M(2012)Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 2601-2608

[6] Cutter D(2013)Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis Ann Oncol 24 101-108

[7] Davies C(2017)Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy Oncotarget 8 55550-55561

[8] Pan H(2017)Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy Anticancer Res 37 4859-4865

[9] Godwin J(2009)Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer Br J Cancer 101 1529-1536

[10] Gray R(2015)Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes Clin Breast Cancer 15 153-160